US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
WO1997031910A1
(en)
|
1996-02-28 |
1997-09-04 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
US6465648B1
(en)
|
1999-06-22 |
2002-10-15 |
Ricoh Company, Ltd. |
Reaction product, process of producing same, electrophotographic photoconductor using same, electrophotographic apparatus having the photoconductor, and process cartridge for electrophotographic apparatus
|
JP2001002661A
(ja)
|
1999-06-22 |
2001-01-09 |
Ricoh Co Ltd |
ニトリル化合物及びその製造方法
|
CA2385589A1
(en)
|
1999-09-17 |
2001-03-22 |
Bing-Yan Zhu |
Inhibitors of factor xa
|
US6632815B2
(en)
|
1999-09-17 |
2003-10-14 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
US20020065303A1
(en)
|
2000-02-01 |
2002-05-30 |
Bing-Yan Zhu |
Bivalent phenylene inhibitors of factor Xa
|
JP2001335476A
(ja)
|
2000-05-29 |
2001-12-04 |
Shionogi & Co Ltd |
三環化合物の新規用途
|
EP1296977A1
(en)
|
2000-06-23 |
2003-04-02 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
AU2001288617A1
(en)
|
2000-09-05 |
2002-03-22 |
Neogenesis Pharmaceuticals Inc. |
Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
|
US20020115106A1
(en)
|
2000-12-22 |
2002-08-22 |
Neogenesis Pharmaceuticals, Inc. |
Methods for forming combinatorial libraries using reductive amination
|
DE10104279A1
(de)
|
2001-01-31 |
2002-08-01 |
Heinz Langhals |
Kompetitive Prionen-Reagenzien und ihre Anwendung in Diagnostik und Therapie
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
EP2168576A3
(en)
|
2001-09-14 |
2010-05-26 |
Shionogi & Co., Ltd. |
Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
BR0316948A
(pt)
|
2002-12-11 |
2005-10-18 |
Lilly Co Eli |
Composto, formulação farmacêutica, e, uso de um composto
|
WO2004054582A1
(en)
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
Combination therapy for the treatment of pain
|
WO2004084824A2
(en)
|
2003-03-24 |
2004-10-07 |
Merck & Co., Inc. |
Biaryl substituted 6-membered heterocyles as sodium channel blockers
|
US7244763B2
(en)
|
2003-04-17 |
2007-07-17 |
Warner Lambert Company Llc |
Compounds that modulate PPAR activity and methods of preparation
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
GB0325956D0
(en)
|
2003-11-06 |
2003-12-10 |
Addex Pharmaceuticals Sa |
Novel compounds
|
US7834013B2
(en)
|
2003-11-19 |
2010-11-16 |
Glaxosmithkline Llc |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
|
CN1930159A
(zh)
|
2004-03-08 |
2007-03-14 |
北卡罗来纳大学查珀尔希尔分校 |
作为抗原生动物药的新的双阳离子咪唑并[1,2-a]吡啶和5,6,7,8-四氢-咪唑并[1,2-a]吡啶化合物
|
JP4859665B2
(ja)
|
2004-03-30 |
2012-01-25 |
武田薬品工業株式会社 |
アルコキシフェニルプロパン酸誘導体
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
US20060019967A1
(en)
|
2004-07-21 |
2006-01-26 |
Su-Ying Wu |
SARS CoV main protease inhibitors
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
JPWO2006038738A1
(ja)
|
2004-10-08 |
2008-05-15 |
武田薬品工業株式会社 |
受容体機能調節剤
|
ES2498972T3
(es)
|
2004-11-03 |
2014-09-26 |
Arena Pharmaceuticals, Inc. |
GPR41 y sus moduladores para el tratamiento de los trastornos relacionados con la insulina
|
CN101106991A
(zh)
|
2005-01-28 |
2008-01-16 |
默克公司 |
抗糖尿病的双环化合物
|
WO2006083781A1
(en)
|
2005-01-31 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
CA2597446A1
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
GB0510141D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B3
|
US7465804B2
(en)
|
2005-05-20 |
2008-12-16 |
Amgen Inc. |
Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
|
EP1907424B1
(en)
|
2005-07-01 |
2015-07-29 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
JP5084503B2
(ja)
|
2005-07-29 |
2012-11-28 |
武田薬品工業株式会社 |
シクロプロパンカルボン酸化合物
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
CA2621949A1
(en)
|
2005-09-14 |
2007-03-22 |
Amgen Inc. |
Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
|
CA2625988A1
(en)
|
2005-10-19 |
2007-04-26 |
Merck & Co., Inc. |
Cetp inhibitors
|
WO2007049050A2
(en)
|
2005-10-27 |
2007-05-03 |
Heptahelix Ab |
Modulators of gpr40 for the treatment of diabetes
|
JP4990789B2
(ja)
|
2005-11-04 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Gpr40とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
|
US20100249175A1
(en)
|
2005-12-02 |
2010-09-30 |
Wilson W David |
Dicationic compounds which selectively recognize G-quadruplex DNA
|
EP1976828B1
(en)
|
2005-12-29 |
2016-12-21 |
Celtaxsys, Inc. |
Diamine derivatives as inhibitors of leukotriene a4 hydrolase
|
EP1987359B1
(en)
|
2006-02-22 |
2015-03-18 |
Philogen S.p.A. |
Vascular tumor markers
|
WO2007106469A2
(en)
|
2006-03-14 |
2007-09-20 |
Amgen Inc. |
Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
|
DE102006012251A1
(de)
|
2006-03-15 |
2007-11-08 |
Grünenthal GmbH |
Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
|
US20110135570A1
(en)
|
2006-03-23 |
2011-06-09 |
Mary Jo Janatpour |
Anti-Tumor Cell Antigen Antibody Therapeutics
|
EP2402319B1
(en)
|
2006-03-31 |
2017-08-30 |
Novartis AG |
DGAT Inhibitors
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
EP1849781A1
(en)
|
2006-04-28 |
2007-10-31 |
Laboratorios del Dr. Esteve S.A. |
Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
|
UA91129C2
(ru)
|
2006-05-09 |
2010-06-25 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
|
DE102006021872B4
(de)
|
2006-05-11 |
2008-04-17 |
Sanofi-Aventis |
4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102006021874B4
(de)
|
2006-05-11 |
2008-03-27 |
Sanofi-Aventis |
4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102006021878A1
(de)
|
2006-05-11 |
2007-11-15 |
Sanofi-Aventis |
Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
MX2008014204A
(es)
|
2006-05-11 |
2008-11-14 |
Sanofi Aventis |
Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilo, metodo para su produccion y su uso como medicamentos.
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
MY154798A
(en)
|
2006-06-27 |
2015-07-31 |
Takeda Pharmaceutical |
Fused cyclic compounds
|
WO2008014236A1
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7714008B2
(en)
|
2006-09-07 |
2010-05-11 |
Amgen Inc. |
Heterocyclic GPR40 modulators
|
WO2008037266A1
(en)
|
2006-09-25 |
2008-04-03 |
Universite Libre De Bruxelles |
Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
|
US8338394B2
(en)
|
2006-10-12 |
2012-12-25 |
Case Western Reserve University |
Methods for treating metabolic diseases
|
JP2010508268A
(ja)
|
2006-10-31 |
2010-03-18 |
メルク エンド カムパニー インコーポレーテッド |
抗糖尿病二環式化合物
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
WO2008065409A2
(en)
|
2006-12-01 |
2008-06-05 |
Betagenon Ab |
Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
|
TW200838526A
(en)
|
2006-12-01 |
2008-10-01 |
Astellas Pharma Inc |
Carboxylic acid derivatives
|
JP2010511635A
(ja)
|
2006-12-04 |
2010-04-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hiv複製の阻害剤
|
JP2010512410A
(ja)
|
2006-12-11 |
2010-04-22 |
ノバルティス アーゲー |
心筋虚血を予防または処置するための方法
|
CA2672438A1
(en)
|
2006-12-20 |
2008-07-03 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
ES2415863T3
(es)
|
2006-12-22 |
2013-07-29 |
Incyte Corporation |
Heterociclos sustituidos como inhibidores de Janus Quinasas
|
MX2009007051A
(es)
|
2006-12-28 |
2009-07-10 |
Abbott Lab |
Inhibidores de la poli(adp-ribosa) polimerasa.
|
WO2008090327A1
(en)
|
2007-01-22 |
2008-07-31 |
Betagenon Ab |
New combination for use in the treatment of cancer
|
WO2008090356A1
(en)
|
2007-01-25 |
2008-07-31 |
Betagenon Ab |
Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
|
WO2008106202A1
(en)
|
2007-02-27 |
2008-09-04 |
Housey Gerard M |
Theramutein modulators
|
BRPI0808888B8
(pt)
|
2007-03-12 |
2021-05-25 |
Cytopia Res Pty Ltd |
composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
|
EP2139843B1
(en)
|
2007-04-16 |
2013-12-25 |
Amgen, Inc |
Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
|
WO2008139987A1
(ja)
|
2007-04-26 |
2008-11-20 |
Japan Science And Technology Agency |
Gタンパク質共役型レセプタ-作動剤
|
US20090214529A9
(en)
|
2007-05-22 |
2009-08-27 |
Taigen Biotechnology Co., Ltd. |
Kinesin inhibitors
|
WO2008144925A1
(en)
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
WO2008156656A2
(en)
|
2007-06-13 |
2008-12-24 |
State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Method for making biaryl compounds, compounds made by the method, and method for their use
|
EP2002838A1
(de)
|
2007-06-13 |
2008-12-17 |
Bayer Schering Pharma AG |
Verwendung von Aryl/Hetarylamid-Derivaten als Modulatoren des EP2-Rezeptors
|
US7968544B2
(en)
|
2007-06-29 |
2011-06-28 |
Gilead Sciences, Inc. |
Modulators of toll-like receptor 7
|
AU2008282728B2
(en)
|
2007-08-02 |
2012-04-19 |
Amgen Inc. |
Pl3 kinase modulators and methods of use
|
CN101842114A
(zh)
|
2007-08-02 |
2010-09-22 |
阿雷斯托生物科学股份有限公司 |
治疗和诊断纤维化、肿瘤侵入、血管生成和转移的方法和组合物
|
TWI649303B
(zh)
|
2007-08-17 |
2019-02-01 |
杜邦股份有限公司 |
製備4-乙醯基-n-〔2-側氧基-2-〔(2,2,2-三氟乙基)胺基〕乙基〕-1-萘甲醯胺之化合物及方法
|
WO2009038204A1
(ja)
|
2007-09-17 |
2009-03-26 |
Pharma Frontier Co., Ltd. |
新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするgタンパク質共役型レセプター作動剤
|
CA2700028A1
(en)
|
2007-09-21 |
2009-04-02 |
Sanofi-Aventis |
(carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament
|
BRPI0817198A2
(pt)
|
2007-09-21 |
2015-03-17 |
Sanofi Aventis |
(ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
|
EP2195304B1
(en)
|
2007-10-08 |
2014-01-08 |
Advinus Therapeutics Private Limited |
Acetamide derivatives as glucokinase activators, their process and medicinal applications
|
MX2010003876A
(es)
|
2007-10-10 |
2010-12-02 |
Amgen Inc |
Moduladores de gpr40 bifenilo- sustituidos.
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
PL2206707T3
(pl)
|
2007-10-24 |
2015-01-30 |
Astellas Pharma Inc |
Związek azolokarboksamidowy lub jego sól
|
NZ584161A
(en)
|
2007-10-26 |
2011-12-22 |
Japan Tobacco Inc |
Spiro-ring compound and use thereof for medical purposes
|
EP2215068B1
(en)
|
2007-10-29 |
2012-06-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2009220163B2
(en)
|
2008-03-06 |
2011-10-06 |
Amgen Inc. |
Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
|
WO2009112445A1
(en)
|
2008-03-10 |
2009-09-17 |
Novartis Ag |
Method of increasing cellular phosphatidyl choline by dgat1 inhibition
|
PE20110308A1
(es)
|
2008-07-08 |
2011-06-10 |
Incyte Corp |
1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
|
CA3092223C
(en)
|
2008-07-21 |
2023-01-03 |
Apogenix Ag |
Tnfsf single chain molecules
|
JP2012503595A
(ja)
|
2008-07-28 |
2012-02-09 |
シダンスク ユニバーシティ |
代謝病の治療用の化合物
|
CA2732437C
(en)
|
2008-08-01 |
2017-11-21 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
US20100130522A1
(en)
|
2008-10-01 |
2010-05-27 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
CA2739888C
(en)
|
2008-10-15 |
2013-11-19 |
Amgen Inc. |
Spirocyclic gpr40 modulators
|
WO2010066682A1
(en)
|
2008-12-08 |
2010-06-17 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
CN102272134B
(zh)
|
2008-12-09 |
2013-10-16 |
吉里德科学公司 |
Toll样受体调节剂
|
WO2010075376A2
(en)
|
2008-12-23 |
2010-07-01 |
Abbott Laboratories |
Anti-viral compounds
|
WO2010082563A1
(ja)
|
2009-01-19 |
2010-07-22 |
第一三共株式会社 |
ヘテロ原子を有する環状化合物
|
JP2012515781A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
架橋および縮合複素環式抗糖尿病化合物
|
US20110312967A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
CA2749663A1
(en)
|
2009-01-23 |
2010-07-29 |
Hubert B. Josien |
Pentafluorosulpholane-containing antidiabetic compounds
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
EP2393359A4
(en)
|
2009-02-09 |
2012-10-03 |
Enanta Pharm Inc |
COMPOUND DIBENZIMIDAZOLE DERIVATIVES
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
NZ595280A
(en)
|
2009-02-27 |
2013-11-29 |
Enanta Pharm Inc |
Hepatitis c virus inhibitors
|
US9150554B2
(en)
|
2009-03-27 |
2015-10-06 |
Presidio Pharmaceuticals, Inc. |
Fused ring inhibitors of hepatitis C
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
BRPI1013937A2
(pt)
|
2009-04-22 |
2016-08-09 |
Astellas Pharma Inc |
compostos de ácido carboxílico
|
PL3002281T3
(pl)
|
2009-05-13 |
2018-02-28 |
Gilead Pharmasset Llc |
Związki przeciwwirusowe
|
WO2010143733A1
(en)
|
2009-06-09 |
2010-12-16 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
NZ591973A
(en)
|
2009-06-11 |
2013-03-28 |
Abbott Lab |
Anti-viral compounds to treat hcv infection
|
TWI491606B
(zh)
|
2009-07-13 |
2015-07-11 |
Gilead Sciences Inc |
調節細胞凋亡信號之激酶的抑制劑
|
CN102781933B
(zh)
|
2009-08-18 |
2016-01-20 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
RU2593261C2
(ru)
|
2009-08-18 |
2016-08-10 |
Вентиркс Фармасьютикалс, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобных рецепторов
|
GB0914856D0
(en)
|
2009-08-25 |
2009-09-30 |
Ark Therapeutics Ltd |
Compounds
|
EP2475254A4
(en)
|
2009-09-11 |
2013-05-22 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
ES2661850T3
(es)
|
2009-09-14 |
2018-04-04 |
Gilead Sciences, Inc. |
Moduladores de receptores del tipo toll
|
US8288404B2
(en)
|
2009-10-06 |
2012-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidine GPR40 modulators
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
NZ598933A
(en)
|
2009-10-22 |
2013-04-26 |
Gilead Sciences Inc |
Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
|
JPWO2011052756A1
(ja)
|
2009-10-30 |
2013-03-21 |
持田製薬株式会社 |
新規3−ヒドロキシ−5−アリールイソキサゾール誘導体
|
EP2499282B1
(en)
|
2009-11-09 |
2015-04-22 |
NeuroGenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
EP2503881B1
(en)
|
2009-11-25 |
2015-05-13 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
EP2513053B1
(en)
|
2009-12-18 |
2017-10-04 |
Ogeda Sa |
Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders
|
WO2011076734A1
(en)
|
2009-12-21 |
2011-06-30 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
|
WO2011076732A1
(en)
|
2009-12-21 |
2011-06-30 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
|
MX2012007474A
(es)
|
2009-12-25 |
2012-08-01 |
Mochida Pharm Co Ltd |
Derivados de 3-hidroxi-5-arilisotiazol novedosos.
|
WO2011080755A1
(en)
|
2009-12-29 |
2011-07-07 |
Advinus Therapeutics Private Limited |
Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
WO2011092284A1
(en)
|
2010-01-29 |
2011-08-04 |
Euroscreen S.A. |
Novel amino acid derivatives and their use as gpr43 receptor modulators
|
WO2011097513A1
(en)
|
2010-02-04 |
2011-08-11 |
Gilead Biologics, Inc |
Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
TW201139438A
(en)
|
2010-03-24 |
2011-11-16 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
JP2013522377A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
BR112012024618A2
(pt)
|
2010-03-30 |
2019-09-24 |
Novartis Ag |
usos de inibidores de dgat1
|
US8686048B2
(en)
|
2010-05-06 |
2014-04-01 |
Rhizen Pharmaceuticals Sa |
Immunomodulator and anti-inflammatory compounds
|
CN102939006A
(zh)
|
2010-05-12 |
2013-02-20 |
范德比尔特大学 |
杂环砜基代谢型谷氨酸受体第4亚型(mglur4)变构增效剂,组合物,以及用以治疗神经性障碍的方法
|
CN103179976A
(zh)
|
2010-05-13 |
2013-06-26 |
印第安纳大学研究及科技有限公司 |
呈现g蛋白偶联受体活性的胰高血糖素超家族肽
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
WO2011152351A1
(ja)
|
2010-05-31 |
2011-12-08 |
小野薬品工業株式会社 |
プリノン誘導体
|
WO2011151436A2
(en)
|
2010-06-04 |
2011-12-08 |
Euroscreen S.A. |
Novel compounds, method for use them and pharmaceutical composition containing them
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
JP2012036168A
(ja)
|
2010-07-15 |
2012-02-23 |
Daiichi Sankyo Co Ltd |
ヘテロ原子を有する環状化合物を含有する医薬組成物
|
WO2012011124A1
(en)
|
2010-07-20 |
2012-01-26 |
Council Of Scientific & Industrial Research |
Ordered mesoporous titanosilicate and the process for the preparation thereof
|
WO2012012627A1
(en)
|
2010-07-22 |
2012-01-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of preventing or treating viral infection
|
AP2016009448A0
(en)
|
2010-08-27 |
2016-09-30 |
Gilead Biologics Inc |
Antibodies to matrix metalloproteinase 9
|
JP5850503B2
(ja)
|
2010-09-14 |
2016-02-03 |
北海道公立大学法人 札幌医科大学 |
筋ジストロフィーを処置するための組成物
|
US8999967B2
(en)
|
2010-09-29 |
2015-04-07 |
Presidio Pharmaceuticals, Inc. |
Tricyclic fused ring inhibitors of hepatitis C
|
CN103237549A
(zh)
|
2010-10-01 |
2013-08-07 |
帆德制药股份有限公司 |
过敏性疾病的治疗方法
|
ES2616449T3
(es)
|
2010-10-01 |
2017-06-13 |
Ventirx Pharmaceuticals, Inc. |
Uso terapéutico de un agonista de TLR y terapia de combinación
|
JP5809157B2
(ja)
|
2010-10-08 |
2015-11-10 |
持田製薬株式会社 |
環状アミド誘導体
|
US9474275B2
(en)
|
2010-11-15 |
2016-10-25 |
Bayer Intellectual Property Gmbh |
Cyanoenamines and their use as fungicides
|
TWI640526B
(zh)
|
2010-11-17 |
2018-11-11 |
基利法瑪席特有限責任公司 |
抗病毒化合物
|
US20130310379A1
(en)
|
2010-11-19 |
2013-11-21 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
EP2646425B1
(en)
|
2010-12-01 |
2015-06-10 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
|
WO2012078802A1
(en)
|
2010-12-08 |
2012-06-14 |
Takeda Pharmaceutical Company Limited |
PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES
|
SG10201510092QA
(en)
|
2010-12-09 |
2016-01-28 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
AR084217A1
(es)
|
2010-12-10 |
2013-05-02 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
US20140364617A1
(en)
|
2010-12-15 |
2014-12-11 |
Abbvie Inc. |
Anti-viral compounds
|
EP2651927A4
(en)
|
2010-12-15 |
2014-06-04 |
Abbvie Inc |
ANTIVIRAL CONNECTIONS
|
EP2651920A4
(en)
|
2010-12-15 |
2014-12-17 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
US20140364616A1
(en)
|
2010-12-15 |
2014-12-11 |
Abbvie Inc. |
Anti-viral compounds
|
EP2651928A4
(en)
|
2010-12-15 |
2014-06-18 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
EP2655334B1
(en)
|
2010-12-22 |
2018-10-03 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
MX348935B
(es)
|
2011-01-12 |
2017-07-03 |
Ventirx Pharmaceuticals Inc |
Benzoazepinas sustituidas como moduladores de receptores tipo toll.
|
HUE032036T2
(en)
|
2011-01-12 |
2017-08-28 |
Ventirx Pharmaceuticals Inc |
Toll-type receptor modulator substituted benzodiazepines
|
AU2012208693B2
(en)
|
2011-01-19 |
2015-02-26 |
Galapagos Nv |
Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
|
JP5998152B2
(ja)
|
2011-01-25 |
2016-09-28 |
ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン |
Bcl−2/bcl−xl阻害剤およびそれを使用する治療方法
|
ES2732311T3
(es)
|
2011-02-07 |
2019-11-21 |
Univ Washington |
Compuestos de manósidos y procedimientos de uso de los mismos
|
AU2012214394B2
(en)
|
2011-02-12 |
2016-08-11 |
Globeimmune, Inc. |
Yeast-based therapeutic for chronic hepatitis B infection
|
AR085252A1
(es)
|
2011-02-17 |
2013-09-18 |
Takeda Pharmaceutical |
Metodo de produccion de derivado de dihidrobenzofurano opticamente activo
|
WO2012129562A2
(en)
|
2011-03-24 |
2012-09-27 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
KR102058946B1
(ko)
|
2011-04-08 |
2019-12-24 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 치료를 위한 피리미딘 유도체
|
US9499467B2
(en)
|
2011-04-08 |
2016-11-22 |
Caldan Therapeutics Limited |
Ortho-fluoro substituted compounds for the treatment of metabolic diseases
|
CN105153146A
(zh)
|
2011-04-27 |
2015-12-16 |
持田制药株式会社 |
新的3-羟基异噻唑1-氧化物衍生物
|
WO2012154608A1
(en)
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
JP5659189B2
(ja)
|
2011-05-13 |
2015-01-28 |
富士フイルム株式会社 |
非共鳴2光子吸収材料、非共鳴2光子吸収記録材料、記録媒体、記録再生方法及び非共鳴2光子吸収化合物
|
ME02986B
(me)
|
2011-05-18 |
2018-10-20 |
Janssen Sciences Ireland Uc |
Derivati hinazolina za tretman viralnih infekcija i drugih bolesтi
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
WO2013009259A1
(en)
|
2011-07-14 |
2013-01-17 |
Biochromix Pharma Ab |
Novel compounds and their use in therapy
|
AR087451A1
(es)
|
2011-08-17 |
2014-03-26 |
Lilly Co Eli |
Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
|
WO2013027802A1
(ja)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
EP2763994A4
(en)
|
2011-10-04 |
2015-08-26 |
Gilead Calistoga Llc |
NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
RU2615999C2
(ru)
|
2011-11-29 |
2017-04-12 |
Оно Фармасьютикал Ко., Лтд. |
Гидрохлорид производного пуринона
|
EA026368B1
(ru)
|
2011-12-21 |
2017-03-31 |
Новира Терапьютикс, Инк. |
Противовирусные агенты против гепатита в
|
EP2800736A1
(en)
|
2012-01-04 |
2014-11-12 |
Sanofi |
3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament
|
CA2860353A1
(en)
|
2012-01-12 |
2013-07-18 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Polycyclic derivatives, preparation method and medical uses thereof
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MX2014008591A
(es)
|
2012-01-16 |
2014-08-22 |
Vertex Pharma |
Piperidinamidas piranoespirociclicas como moduladores de canales de iones.
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(en)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
|
AU2013218072B2
(en)
|
2012-02-08 |
2017-08-31 |
Janssen Sciences Ireland Uc |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
US9181186B2
(en)
|
2012-02-13 |
2015-11-10 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
EP2816023A4
(en)
|
2012-02-13 |
2015-09-09 |
Takeda Pharmaceutical |
AROMATIC CORE COMPOUND
|
IN2014MN01839A
(es)
|
2012-02-28 |
2015-07-03 |
Piramal Entpr Ltd |
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
EP2831060B1
(en)
|
2012-03-31 |
2016-05-04 |
F.Hoffmann-La Roche Ag |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
EP2852585A1
(en)
|
2012-05-11 |
2015-04-01 |
AbbVie Inc. |
Nampt inhibitors
|
AR091023A1
(es)
|
2012-05-11 |
2014-12-30 |
Abbvie Inc |
Inhibidores del nampt
|
US8633182B2
(en)
*
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
NZ724616A
(en)
|
2012-06-08 |
2018-06-29 |
Gilead Sciences Inc |
Macrocyclic inhibitors of flaviviridae viruses
|
WO2013185103A1
(en)
|
2012-06-08 |
2013-12-12 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of flaviviridae viruses
|
WO2014014530A1
(en)
|
2012-07-17 |
2014-01-23 |
Mylari Banavara L |
Ursolic acid salts for treating diabetes and obesity
|
JP2015127299A
(ja)
|
2012-07-19 |
2015-07-09 |
武田薬品工業株式会社 |
固形製剤
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2014023813A1
(en)
|
2012-08-10 |
2014-02-13 |
Janssen R&D Ireland |
Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
|
US9024042B2
(en)
|
2012-08-27 |
2015-05-05 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
HUE031400T2
(en)
|
2012-08-28 |
2017-07-28 |
Janssen Sciences Ireland Uc |
Condensed bicyclic sulfamoyl derivatives and their use as medicaments for the treatment of hepatitis B
|
SG10201709133QA
(en)
|
2012-08-28 |
2017-12-28 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
AU2013311705A1
(en)
|
2012-09-10 |
2015-02-05 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
|
US20140073631A1
(en)
|
2012-09-12 |
2014-03-13 |
Vymed Corporation |
Antiviral and antimicrobial compounds
|
TW201427995A
(zh)
|
2012-09-24 |
2014-07-16 |
Gilead Sciences Inc |
抗ddr1抗體
|
EP3150582A1
(en)
|
2012-10-02 |
2017-04-05 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
HUE037064T2
(hu)
|
2012-10-10 |
2018-08-28 |
Janssen Sciences Ireland Uc |
Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
|
US10034939B2
(en)
|
2012-10-26 |
2018-07-31 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
US20140128333A1
(en)
|
2012-11-02 |
2014-05-08 |
Maqui New Life S.A. |
Compounds, Compositions, and Methods for Decreasing Intestinal Glucose Uptake and Inducing Incretin Release
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
KR101268466B1
(ko)
|
2012-11-12 |
2013-06-04 |
유병수 |
사축형 윈드 터빈
|
CA2891574A1
(en)
|
2012-11-16 |
2014-05-22 |
Bristol-Myers Squibb Company |
Dihydropyrazole gpr40 modulators
|
JP6297055B2
(ja)
|
2012-11-16 |
2018-03-20 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体
|
CA2891535A1
(en)
|
2012-11-16 |
2014-05-22 |
Bristol-Myers Squibb Company |
Dihydropyrazole gpr40 modulators
|
CN105121426B
(zh)
|
2012-11-16 |
2017-03-29 |
百时美施贵宝公司 |
吡咯烷gpr40调节剂
|
RU2015124002A
(ru)
|
2012-11-20 |
2017-01-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы
|
CN104822675A
(zh)
|
2012-11-28 |
2015-08-05 |
勃林格殷格翰国际有限公司 |
新的茚满基氧基二氢苯并呋喃乙酸
|
EP3763367A1
(en)
|
2012-12-06 |
2021-01-13 |
Celgene Quanticel Research, Inc. |
Pyridine-pyrazole derivatives as histone demethylase inhibitors
|
JP6283862B2
(ja)
|
2012-12-07 |
2018-02-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシジヒドロベンゾフラニル酢酸
|
ES2658597T3
(es)
|
2012-12-19 |
2018-03-12 |
Celgene Quanticel Research, Inc. |
Inhibidores de histona desmetilasa
|
BR112015014968A2
(pt)
|
2012-12-21 |
2017-07-11 |
Quanticel Pharmaceuticals Inc |
inibidores de histona-desmetilase
|
JP6125663B2
(ja)
|
2012-12-21 |
2017-05-10 |
ギリアード カリストガ エルエルシー |
ホスファチジルイノシトール3−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン
|
TW201437203A
(zh)
|
2012-12-21 |
2014-10-01 |
Gilead Calistoga Llc |
磷脂醯肌醇3-激酶之抑制劑
|
EP2953681B1
(en)
|
2013-02-06 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
New indanyloxydihydrobenzofuranylacetic acids
|
EP2958900B1
(en)
|
2013-02-21 |
2019-04-10 |
Janssen Sciences Ireland Unlimited Company |
2-aminopyrimidine derivatives for the treatment of viral infections
|
CN104994848A
(zh)
|
2013-02-22 |
2015-10-21 |
默沙东公司 |
抗糖尿病二环化合物
|
SG10201707027SA
(en)
|
2013-02-27 |
2017-09-28 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
WO2014134243A1
(en)
|
2013-02-27 |
2014-09-04 |
Regents Of The University Of Michigan |
Pharmaceutical compounds and use of same in cancer and tauopathies
|
AU2014222641B2
(en)
|
2013-02-28 |
2018-03-15 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
|
AU2014221489B2
(en)
|
2013-02-28 |
2018-03-08 |
Tiumbio Co., Ltd. |
Tricyclic compound and use thereof
|
CA2903473A1
(en)
|
2013-03-12 |
2014-10-09 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
MX2015011898A
(es)
|
2013-03-13 |
2016-05-05 |
Genentech Inc |
Compuestos de pirazolo y usos de los mismos.
|
JP6276378B2
(ja)
|
2013-03-14 |
2018-02-07 |
セルジーン クオンティセル リサーチ,インク. |
ヒストンデメチラーゼ阻害剤
|
WO2014145817A2
(en)
|
2013-03-15 |
2014-09-18 |
Children's Medical Center Corporation |
Novel therapeutic target for the treatment of cancers and related therapies and methods
|
JP6332654B2
(ja)
|
2013-03-15 |
2018-05-30 |
セルジーン クオンティセル リサーチ,インク. |
ヒストンデメチラーゼ阻害剤
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
JP6419155B2
(ja)
|
2013-04-03 |
2018-11-07 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
AR096041A1
(es)
|
2013-04-17 |
2015-12-02 |
Piramal Entpr Ltd |
Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
|
KR101569522B1
(ko)
|
2013-04-18 |
2015-11-17 |
현대약품 주식회사 |
신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
TW201512193A
(zh)
|
2013-05-17 |
2015-04-01 |
Hoffmann La Roche |
用於治療及防治b型肝炎病毒感染之新穎6-橋聯雜芳基二氫嘧啶
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
SI2997019T1
(sl)
|
2013-05-17 |
2018-12-31 |
Janssen Sciences Ireland Uc, |
Derivati sulfamoiliofenamida in njihova uporaba kot zdravila za zdravljenje hepatitisa B
|
WO2014187343A1
(zh)
|
2013-05-22 |
2014-11-27 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
SI3008053T1
(en)
|
2013-06-14 |
2018-06-29 |
Gilead Calistoga Llc |
PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
|
CN104507921B
(zh)
|
2013-07-02 |
2017-02-22 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
US10478445B2
(en)
|
2013-07-03 |
2019-11-19 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
EP3019615B1
(en)
|
2013-07-12 |
2021-04-07 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Cystobactamides
|
PL3024819T3
(pl)
|
2013-07-25 |
2018-08-31 |
Janssen Sciences Ireland Uc |
Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
|
WO2015010655A1
(zh)
|
2013-07-26 |
2015-01-29 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
MX2016001304A
(es)
|
2013-07-30 |
2016-04-07 |
Gilead Connecticut Inc |
Polimorfo de inhibidores de syk.
|
JP6397410B2
(ja)
|
2013-08-09 |
2018-09-26 |
武田薬品工業株式会社 |
芳香環化合物
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
CN105473595A
(zh)
|
2013-08-23 |
2016-04-06 |
福建海西新药创制有限公司 |
治疗糖尿病的羧酸化合物
|
CA2922567A1
(en)
|
2013-08-26 |
2015-03-05 |
Purdue Pharma L.P. |
Azaspiro[4.5]decane derivatives and use thereof
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
WO2015032328A1
(zh)
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
CA2923184A1
(en)
|
2013-09-04 |
2015-03-12 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
PL3363790T3
(pl)
|
2013-09-06 |
2020-07-27 |
Aurigene Discovery Technologies Limited |
Pochodne 1,2,4-oksadiazolu jako immunomodulatory
|
DK3043865T3
(da)
|
2013-09-11 |
2021-02-01 |
Univ Claude Bernard Lyon |
Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
|
WO2015044073A1
(en)
|
2013-09-26 |
2015-04-02 |
Boehringer Ingelheim International Gmbh |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
ES2655518T3
(es)
|
2013-10-23 |
2018-02-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
IN2013MU03577A
(es)
|
2013-11-14 |
2015-07-31 |
Cadila Healthcare Ltd |
|
US9115113B2
(en)
|
2013-11-14 |
2015-08-25 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US10519115B2
(en)
|
2013-11-15 |
2019-12-31 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US10584115B2
(en)
|
2013-11-21 |
2020-03-10 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine BMI-1 inhibitors
|
CA2929436C
(en)
|
2013-11-27 |
2021-06-15 |
Euroscreen Sa |
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
|
JP6441928B2
(ja)
|
2013-11-28 |
2018-12-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシフェニルシクロプロパンカルボン酸
|
WO2015084692A1
(en)
|
2013-12-04 |
2015-06-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2015085238A1
(en)
|
2013-12-05 |
2015-06-11 |
The Regents Of The University Of California, A California Corporation |
Inhibitors of lpxc
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎***并吡啶化合物
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
UY35898A
(es)
|
2013-12-23 |
2015-07-31 |
Gilead Sciences Inc |
?compuestos inhibidores de syk y composiciones que los comprenden?.
|
EA201691150A1
(ru)
|
2014-01-10 |
2016-10-31 |
Эли Лилли Энд Компани |
Соединения изопропилтриазолопиридина
|
BR112016013874A2
(pt)
|
2014-01-10 |
2017-08-08 |
Lilly Co Eli |
Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
EP3099685B1
(en)
|
2014-01-30 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
WO2015119899A1
(en)
|
2014-02-06 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
CN105980378B
(zh)
|
2014-02-06 |
2019-09-27 |
爱尔兰詹森科学公司 |
氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
|
SI3114128T1
(sl)
|
2014-03-07 |
2019-04-30 |
F. Hoffmann-La Roche Ag |
Novi 6-spojeni heteroarildihidropirimidini za zdravljenje in preprečevanje okužbe z virusom hepatitisa B
|
CA2942761A1
(en)
|
2014-03-18 |
2015-09-24 |
Iteos Therapeutics |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
JP6554117B2
(ja)
|
2014-04-04 |
2019-07-31 |
イオメット ファーマ リミテッド |
医療で使用されるインドール誘導体
|
US20170029774A1
(en)
|
2014-04-10 |
2017-02-02 |
Seattle Children's Hospital (dba Seattle Children' Research Institute) |
Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
WO2015171757A1
(en)
|
2014-05-07 |
2015-11-12 |
Bristol-Myers Squibb Company |
Pyrrolidine gpr40 modulators
|
SI3140296T1
(en)
|
2014-05-07 |
2018-06-29 |
Bristol-Myers Squibb Company |
PIROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES AS SUITABLE DISEASE
|
MX2016014118A
(es)
|
2014-05-07 |
2017-02-09 |
Bristol Myers Squibb Co |
Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes.
|
CA2948080A1
(en)
|
2014-05-13 |
2015-11-19 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US10987322B2
(en)
|
2014-06-06 |
2021-04-27 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
US10471028B2
(en)
|
2014-06-13 |
2019-11-12 |
University Of Rochester |
Small molecule efflux pump inhibitors
|
GB201411239D0
(en)
|
2014-06-25 |
2014-08-06 |
Takeda Pharmaceutical |
Novel compounds
|
GB201411236D0
(en)
|
2014-06-25 |
2014-08-06 |
Takeda Pharmaceutical |
Novel compounds
|
TW201613878A
(en)
|
2014-07-09 |
2016-04-16 |
Janssen Pharmaceutica Nv |
Pyrazine GPR40 agonists for the treatment of type II diabetes
|
WO2016012470A1
(en)
|
2014-07-25 |
2016-01-28 |
F. Hoffmann-La Roche Ag |
New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
|
EP3174537B1
(en)
|
2014-07-29 |
2021-06-23 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
WO2016022448A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
RU2664329C1
(ru)
|
2014-08-14 |
2018-08-16 |
Ф. Хоффманн-Ля Рош Аг |
Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
US9802941B2
(en)
|
2014-08-27 |
2017-10-31 |
Gilead Sciences, Inc. |
Compounds and methods for inhibiting histone demethylases
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
MA40132B1
(fr)
|
2014-09-11 |
2019-04-30 |
Bristol Myers Squibb Co |
Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
|
UY35733A
(es)
|
2014-09-12 |
2016-04-01 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c.
|
KR20170090408A
(ko)
|
2014-09-19 |
2017-08-07 |
매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 |
벤조-헤테로시클릭 화합물 및 이의 적용
|
AU2015320675B2
(en)
|
2014-09-26 |
2018-10-18 |
Gilead Sciences, Inc. |
Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
WO2016060963A1
(en)
|
2014-10-14 |
2016-04-21 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
CA2960944C
(en)
|
2014-10-17 |
2019-09-10 |
Hyundai Pharm Co., Ltd. |
Use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivatives in combination with a secondary active ingredient for the treatment of metabolic diseases
|
SG10201903578VA
(en)
*
|
2014-10-24 |
2019-05-30 |
Bristol Myers Squibb Co |
Indole carboxamides compounds useful as kinase inhibitors
|
KR101857146B1
(ko)
|
2014-10-28 |
2018-05-11 |
삼성에스디아이 주식회사 |
유기 광전자 소자 및 표시 장치
|
CN111943890B
(zh)
|
2014-11-03 |
2023-10-31 |
艾欧米制药有限公司 |
药用化合物
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CA2969456A1
(en)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
WO2016100236A2
(en)
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
AR103222A1
(es)
|
2014-12-23 |
2017-04-26 |
Hoffmann La Roche |
Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
JP6506845B2
(ja)
|
2014-12-30 |
2019-04-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
CN107109497A
(zh)
|
2014-12-31 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
|
BR112017014770A2
(pt)
|
2015-01-08 |
2018-01-16 |
Advinus Therapeutics Ltd |
compostos bicíclicos, composições e aplicações médicas dos mesmos
|
MA41338B1
(fr)
|
2015-01-16 |
2019-07-31 |
Hoffmann La Roche |
Composés de pyrazine pour le traitement de maladies infectieuses
|
CN107208102B
(zh)
|
2015-01-27 |
2021-07-06 |
豪夫迈·罗氏有限公司 |
重组hbv cccdna、其产生方法及其用途
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016127135A1
(en)
|
2015-02-06 |
2016-08-11 |
Unity Biotechnology, Inc. |
Compounds and uses in treatment of senescence-associated conditons
|
WO2016128335A1
(en)
|
2015-02-11 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
SG11201706901TA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
Therapeutic cyclic compounds as immunomodulators
|
CN107427476A
(zh)
|
2015-03-10 |
2017-12-01 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物
|
MX2017011614A
(es)
|
2015-03-10 |
2018-03-23 |
Aurigene Discovery Tech Ltd |
Compuestos de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores.
|
WO2016142894A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
CA3220902A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
CN104876912B
(zh)
|
2015-04-08 |
2017-07-21 |
苏州云轩医药科技有限公司 |
Wnt信号通路抑制剂及其应用
|
CA2985642A1
(en)
|
2015-05-15 |
2016-11-24 |
Gilead Sciences, Inc. |
Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
|
CN108174607A
(zh)
|
2015-05-29 |
2018-06-15 |
朱诺治疗学股份有限公司 |
用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
|
AR104020A1
(es)
|
2015-06-04 |
2017-06-21 |
Kura Oncology Inc |
Métodos y composiciones para inhibir la interacción de menina con proteínas mill
|
WO2016197987A1
(zh)
|
2015-06-12 |
2016-12-15 |
杭州英创医药科技有限公司 |
作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
|
EP3322420B1
(en)
|
2015-07-13 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
WO2017025368A1
(en)
|
2015-08-07 |
2017-02-16 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US9920040B2
(en)
|
2015-08-12 |
2018-03-20 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
US9908873B2
(en)
|
2015-08-12 |
2018-03-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
WO2017031392A1
(en)
|
2015-08-20 |
2017-02-23 |
University Of Florida Research Foundation, Incorporated |
Lipid compounds for treatment of obesity, hypertension and metabolic syndrome
|
JP2018526405A
(ja)
|
2015-09-09 |
2018-09-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
[{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用
|
KR20180051625A
(ko)
|
2015-09-17 |
2018-05-16 |
노파르티스 아게 |
증진된 효능을 갖는 car t 세포 요법
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
TW201718581A
(zh)
|
2015-10-19 |
2017-06-01 |
英塞特公司 |
作為免疫調節劑之雜環化合物
|
EP3370699A1
(en)
|
2015-11-04 |
2018-09-12 |
Incyte Corporation |
Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
|
TWI763641B
(zh)
|
2015-11-19 |
2022-05-11 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
WO2017099034A1
(ja)
|
2015-12-07 |
2017-06-15 |
国立大学法人京都大学 |
Pd-1シグナル阻害剤の併用療法
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
TWI767896B
(zh)
|
2015-12-22 |
2022-06-21 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
WO2017107979A1
(en)
|
2015-12-24 |
2017-06-29 |
Genentech, Inc. |
Tdo2 inhibitors
|
EP3190103A1
(en)
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
AU2017221441A1
(en)
|
2016-02-17 |
2018-10-04 |
Children's Medical Center Corporation |
FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9798514B2
(en)
|
2016-03-09 |
2017-10-24 |
Spotify Ab |
System and method for color beat display in a media content environment
|
EP3432878A1
(de)
|
2016-03-23 |
2019-01-30 |
Symrise AG |
Homovanillinsäure-ester zum reduzieren oder inhibieren der fettsäureaufnahme im dünndarm
|
WO2017172505A1
(en)
|
2016-03-29 |
2017-10-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US10195178B2
(en)
|
2016-04-11 |
2019-02-05 |
Janssen Pharmaceutica Nv |
GPR40 agonists in anti-diabetic drug combinations
|
WO2017180571A1
(en)
|
2016-04-11 |
2017-10-19 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
|
US20190062272A1
(en)
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
US20170320875A1
(en)
|
2016-05-06 |
2017-11-09 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN109153626B
(zh)
|
2016-05-23 |
2022-06-03 |
天津红日药业股份有限公司 |
2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
RU2018145184A
(ru)
|
2016-05-26 |
2020-06-26 |
Мерк Патент Гмбх |
Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования
|
EP3464279B1
(en)
|
2016-05-26 |
2021-11-24 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
AU2017281285C1
(en)
|
2016-06-20 |
2022-05-12 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
KR102401963B1
(ko)
*
|
2016-06-27 |
2022-05-25 |
케모센트릭스, 인크. |
면역조절제 화합물
|
CA3029991A1
(en)
|
2016-07-08 |
2018-01-11 |
Bristol-Myers Squibb Company |
1,3-dihydroxy-phenyl derivatives useful as immunomodulators
|
CA3030773A1
(en)
|
2016-08-03 |
2018-02-08 |
Arising International, Inc. |
Symmetric or semi-symmetric compounds useful as immunomodulators
|
EP3281937A1
(en)
|
2016-08-09 |
2018-02-14 |
Dompé farmaceutici S.p.A. |
Sulfonamides as gpr40- and gpr120-agonists
|
US10563620B2
(en)
|
2016-08-12 |
2020-02-18 |
Rolls-Royce North American Technologies Inc. |
Expandable exhaust cone
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
US10734026B2
(en)
|
2016-09-01 |
2020-08-04 |
Facebook, Inc. |
Systems and methods for dynamically providing video content based on declarative instructions
|
TW201823199A
(zh)
|
2016-09-02 |
2018-07-01 |
美商北極星藥品公司 |
免疫檢查點抑制劑、組成物及其方法
|
WO2018051254A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
WO2018051255A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
WO2018053302A1
(en)
|
2016-09-19 |
2018-03-22 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
|
WO2018081047A1
(en)
|
2016-10-25 |
2018-05-03 |
Janssen Pharmaceutica Nv |
Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
|
WO2018077699A1
(en)
|
2016-10-25 |
2018-05-03 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018095877A1
(en)
*
|
2016-11-28 |
2018-05-31 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
KR102599339B1
(ko)
|
2016-12-20 |
2023-11-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 화합물
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
RU2019122602A
(ru)
|
2016-12-20 |
2021-01-22 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
|
TWI808955B
(zh)
|
2016-12-22 |
2023-07-21 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
MA47120A
(fr)
|
2016-12-22 |
2021-04-28 |
Incyte Corp |
Dérivés pyridine utilisés en tant qu'immunomodulateurs
|
US20180179201A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
SG10202106743QA
(en)
|
2016-12-22 |
2021-08-30 |
Incyte Corp |
Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
|
WO2018121560A1
(zh)
|
2016-12-29 |
2018-07-05 |
深圳微芯生物科技有限责任公司 |
脲类化合物、其制备方法及其应用
|
JP7050792B2
(ja)
|
2017-01-26 |
2022-04-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
US10913720B2
(en)
|
2017-01-26 |
2021-02-09 |
Boehringer Ingelheim International Gmbh |
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US10793530B2
(en)
|
2017-01-26 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
JP7023969B2
(ja)
|
2017-01-26 |
2022-02-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
|
EP3573965B1
(en)
|
2017-01-26 |
2021-06-23 |
Boehringer Ingelheim International GmbH |
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018146008A1
(en)
|
2017-02-08 |
2018-08-16 |
Boehringer Ingelheim International Gmbh |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
EP3596075B1
(en)
|
2017-03-15 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Azaindoles as inhibitors of hpk1
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
JP7150745B2
(ja)
|
2017-03-27 |
2022-10-11 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤としての置換イソキノリン誘導体
|
BR112019019555A2
(pt)
|
2017-03-30 |
2020-04-22 |
Hoffmann La Roche |
composto de fórmula i, composição farmacêutica, método de inibição de hpk1, método para melhorar uma resposta imune, método para tratar um distúrbio e uso do composto
|
EP3601284B1
(en)
|
2017-03-30 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Naphthyridines as inhibitors of hpk1
|
WO2018181847A1
(ja)
|
2017-03-31 |
2018-10-04 |
武田薬品工業株式会社 |
芳香環化合物
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
JOP20180040A1
(ar)
*
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
CN108794422B
(zh)
|
2017-04-26 |
2022-07-01 |
南京圣和药业股份有限公司 |
作为pd-l1抑制剂的杂环类化合物
|
WO2019008156A1
(en)
|
2017-07-07 |
2019-01-10 |
Rijksuniversiteit Groningen |
INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
|
US10919852B2
(en)
|
2017-07-28 |
2021-02-16 |
Chemocentryx, Inc. |
Immunomodulator compounds
|
CN111225665B
(zh)
|
2017-08-08 |
2023-12-08 |
凯莫森特里克斯股份有限公司 |
大环免疫调节剂
|
CN109400522B
(zh)
|
2017-08-18 |
2023-04-28 |
上海轶诺药业有限公司 |
一种具有pd-l1抑制活性的化合物、其制备方法及用途
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
KR20200058506A
(ko)
|
2017-10-03 |
2020-05-27 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
WO2019074241A1
(ko)
|
2017-10-11 |
2019-04-18 |
정원혁 |
페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
|
CN109678796B
(zh)
|
2017-10-19 |
2023-01-10 |
上海长森药业有限公司 |
Pd-1/pd-l1小分子抑制剂及其制备方法和用途
|
CN109988144A
(zh)
|
2017-12-29 |
2019-07-09 |
广州再极医药科技有限公司 |
芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
|
EP4227302A1
(en)
|
2018-02-13 |
2023-08-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
WO2019165043A2
(en)
|
2018-02-22 |
2019-08-29 |
Chemocentryx, Inc. |
Indane-amines as pd-l1 antagonists
|
WO2019175897A1
(en)
|
2018-03-13 |
2019-09-19 |
Jubilant Biosys Limited |
Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
|
CN111788193B
(zh)
|
2018-03-13 |
2023-04-04 |
广东东阳光药业有限公司 |
Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
|
ES2940750T3
(es)
|
2018-03-30 |
2023-05-11 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
PE20211918A1
(es)
|
2018-05-11 |
2021-09-28 |
Incyte Corp |
Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1
|
CN112424185A
(zh)
|
2018-07-13 |
2021-02-26 |
广州丹康医药生物有限公司 |
含苯环的化合物、其制备方法及应用
|
PT3820572T
(pt)
|
2018-07-13 |
2023-11-10 |
Gilead Sciences Inc |
Inibidores pd-1/pd-l1
|